Rituxan Could Be Top Source Of Price Inflation Rebates In Medicare Part B
Executive Summary
HHS Office of Inspector General estimates $1.4bn to $1.8bn could have been saved in Medicare Part B in 2015 if manufacturers provided rebates when drug prices increased faster than inflation.
You may also be interested in...
Number One With A Bullet: Eylea Takes Top Spot In Medicare Part B Drugs
Regeneron’s Eylea is the new holder of the number one spot in Medicare Part B prescription drug payments. It is also the fastest growing entrant on the top-ten list tracked by MedPAC. That is a sign of great commercial success – but could be an uncomfortable spotlight.
Part B Drug Rebate Ideas Not Drawing CMS Attention, Despite OIG Prodding
The HHS Office of Inspector General finds Medicare Part B could have saved $3.1 billion on 60 of the costliest drugs by applying Medicaid-level rebates, which the office says “warrants further deliberation.” But noting Part B drug rebates are not actively under consideration by the administration or Congress, CMS says it will not devote resources to examining the issue.
Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs
The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026.